Why Some People Lose More Weight on GLP-1 Medications?
Clinician's Perspective:
• Researchers identified a specific genetic variant in the GLP1R gene (GLP-1 receptor) (the primary cellular docking site for these drugs) that directly influences how much weight a person loses.
• Individuals carrying a specific version of this gene (rs10305420) experienced an additional 0.76 kg of weight loss per copy of the gene allele (variant form) compared to those without it.
• Side Effect Predictors: Genetic variations in both the GLP1R and GIPR (Gastric Inhibitory Polypeptide Receptor) genes were linked to increased rates of nausea and vomiting, providing a biological explanation for why some patients struggle with tolerability.
• Tirzepatide Specificity: A variant in the GIPR gene was found to predict vomiting specifically for those using tirzepatide, a dual-action medication, but had no effect on those using semaglutide.
• Precision Modeling for Response to Weight Loss Medication: By combining genetic data with clinical factors like age, sex, race, duration of treatment, drug dosage and BMI, researchers created a model that explains 25% of the variation in how people respond to these treatments.
• Lifestyle differences remain a significant factor for weight loss response. It is essential to adopt a healthy, active lifestyle.
While GLP-1 receptor agonists like semaglutide and tirzepatide have revolutionized the management of Adiposity (the condition of having a high level of body fat), clinical experience shows a "response gap." Some individuals achieve transformative weight loss, while others experience minimal change or debilitating side effects. A new study published in *Nature* has begun to map the genetics behind this variation, suggesting that our genetic blueprint determines the efficiency of these metabolic interventions.
The research focused on the Pharmacodynamics (how a drug acts on the body) of these medications. The team identified a missense variant—a single-letter change in the DNA code—located in the GLP1R gene. This gene provides the instructions for building the receptor that the medication must "plug into" to signal the brain to reduce hunger. For every copy of this genetic variant (rs10305420) a person carries, they lost an additional 0.76 kg of weight. Researchers suggest this variant may enhance the stability of the receptor, effectively increasing the drug's effect by ensuring more receptors are available on the cell surface to receive the medication.
The study also addressed the common "bottleneck" of GLP-1 therapy: gastrointestinal side effects like bloating and nausea. By examining the GIPR gene—the second target for dual-agonist medications like tirzepatide—the data revealed a specific mutation (rs1800437) that serves as a partial loss-of-function. In tirzepatide users, this genetic quirk was associated with an 84% increase in the odds of experiencing severe vomiting. This suggests that for some, the body’s internal buffering system against nausea is genetically compromised, making certain medications harder to tolerate than others.
Beyond individual genes, the researchers developed a precision medicine model. While non-genetic factors like sex, starting BMI, and drug dosage remain the primary drivers of weight loss, the inclusion of genetic markers significantly improved the ability to predict a patient's journey. In a separate validation group, the model successfully stratified patients into high and low responders, demonstrating that the "one-size-fits-all" approach to dosing may soon be replaced by a personalized system optimized for an individual’s Proteomics (the large-scale study of proteins expressed by a genome).
These findings suggest that the massive variation seen in weight loss clinics is not merely a matter of willpower or lifestyle adherence, but a reflection of innate biological hardware. As we move toward a future of "Precision Obesity Medicine," genetic screening could potentially allow clinicians to select the right molecule and the right dose for a patient before the first injection is even administered.
Evidence Strength: This large-scale observational study provides high-quality evidence through its robust sample size (n=27,885) and successful independent replication in a clinical EHR cohort, though it is primarily limited by the self-reported nature of some side-effect data. Final Rating: ★★★★☆
Source: Read the full study
